HIV-1 drug resistance in treatment-naive patients has a significant impact on the individual patient as well as implications for the wider population. These effects are amplified in the context of resource-limited settings, which are rapidly expanding access to antiretroviral therapy.
Methods
This cross-sectional survey at a single treatment site in Kingston, Jamaica was designed to identify the prevalence of HIV-1 drug-resistant mutations in chronically infected, treatment-naive patients. Mutations were identified using the Stanford HIV database algorithm and the World Health Organization (WHO) HIV Drug Resistance (HIVDR) surveillance mutations.
Results
The inclusion of 103 cases in the study resulted in 79 (76.6%) amplifiable samples. Genotype analysis revealed that 12.6% (95% CI 5.3, 19.9) were identified as having clinically significant mutations, while 10.1% (95% CI 3.5, 16.7) had WHO HIVDR surveillance mutations.
Conclusions
According to the WHO standard, this study population has a moderate level of HIVDR in treatment-naive patients and strongly implies the need to introduce HIVDR surveillance in Jamaica.
References
1.
Jamaica National HIV/STI Programme.United Nations General Assembly special session country progress report 2010. Jamaica: UNAIDS2010.
2.
NadaiY., EyzaguirreL.M., SillA.HIV-1 epidemic in the Caribbean is dominated by subtype B. PLoS ONE2009; 4: e4814.
3.
HeslopO.D., SmikleM.F., DeerD.Human immunodeficiency virus type-1 (HIV-1) subtypes in Jamaica. West Indian Med J2005; 54: 279–282.
4.
FigueroaJ.P., DuncanJ., ByfieldL.A comprehensive response to the HIV/AIDS epidemic in Jamaica. A review of the past 20 years. West Indian Med J2008; 57: 562.
HamiltonC.L., EyzaguirreL.M., AmarakoonI.I.Analysis of protease and reverse transcriptase genes of HIV for antiretroviral drug resistance in Jamaican adults. AIDS Res Hum Retroviruses2012; 28: 923–927.
7.
WensingA.M.J., BoucherC.A.B.Worldwide transmission of drug-resistant HIV. AIDS Rev2003; 5: 140–155.
8.
UK Group on Transmitted HIV Drug Resistance.Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ2005; 331: 1368.
9.
RheeS.Y., BlancoJ.L., LiuT.F., VargheseV., TangM., ShaferR.W.Surveillance drug resistance mutation prevalence in untreated populations in Sub-Saharan Africa (SSA) and South/South East Asia (SSEA): regional differences and temporal trends.19th Conference on Retrovirus and Opportunistic Infections. 5–8 March 2012, Seattle, WA, USA. Poster 739.
10.
MyersJ.E., TaylorB.S., Rojas FerminR.A.Transmitted drug resistance among antiretroviral-naive patients with established HIV type 1 Infection in Santo Domingo, Dominican Republic and review of the Latin American and Caribbean literature. AIDS Res Hum Retroviruses2012; 28: 667–674.
11.
LiuT.F., ShaferR.W.Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis2006; 42: 1608–1618.
12.
BennettD.E., CamachoR.J., OteleaD.Drug resistance mutations for surveillance of transmitted HIV-1 drug resistance: 2009 update. PLoS ONE2009; 4: e4724.
13.
JordanM.R., BennettD.E., BertagnolioS., GilkesC.F., SutherlandD.World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther2008; 13Suppl 2: 15–23.
14.
GuptaR.K., JordanM.R., SultanB.J.Global trends in ART resistance in untreated HIV-1 infected individuals following ART roll-out in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet2012; 380: 1250–1258.
15.
ShaferR.W., RheeS.Y., PillayD.HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS2007; 21: 215–223.
16.
NicastriE., SarmatiL., d'EttorreG.Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy. J Med Virol2003; 69: 1–6.
17.
SvicherV., SingT., SantoroM.M.Involvement of novel HIV-1 reverse transcriptase mutations in the regulation of NNRTI resistance. Antivir Ther2006; 11Suppl 1: S165.
18.
DeGruttolaV., DixL., D'AquilaR.The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther2000; 5: 41–48.
19.
FideliU.S., AllenS.A., MusondaR.Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses2001; 17: 901–910.
20.
JordanM.R., BennettD.E., WainbergM.A.Update on World Health Organization HIV drug resistance prevention and assessment of strategy: 2004–2011. Clin Infect Dis2012; 54Suppl 4: S245–S249.
